Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Genetic Tech Spn Ads (GENE)

Genetic Tech Spn Ads (GENE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Genetic Technologies CEO to Participate in Investor Webinar and Q&A Session on June 24, 2020

Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the "Company") is pleased to announce that its interim-CEO Dr. George Muchnicki will share insight into the Company's...

GENE : 2.32 (+1.75%)
US Patent Office Grants Key Risk Test Patent

Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the "Company") is pleased to announce the issuance of US Patent No: US 10,683,549, Methods for assessing risk of developing...

GENE : 2.32 (+1.75%)
Genetic Technologies Announces Closing of $8.0 Million Public Offering

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the "Company"), a leader in the development of genetic risk assessment tests, today announced the closing of its previously announced public offering...

GENE : 2.32 (+1.75%)
Genetic Technologies Announces Pricing of $8.0 Million Public Offering

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the "Company"), a leader in the development of genetic risk assessment tests, today announced that it has priced a public offering of 4,000,000 ...

GENE : 2.32 (+1.75%)
Genetic Technologies Provides Operational Update - Successful Prototype Polygenic Risk Score for COVID-19 Created

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the "Company") provides the following operational updates:

GENE : 2.32 (+1.75%)
Genetic Technologies - Accelerated development of new COVID-19 Polygenic Risk Test for Risk of Developing Life-Threatening Complications

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is to commence accelerating development of a polygenic risk score (PRS) test to predict an individual's risk of developing life-threatening complications...

GENE : 2.32 (+1.75%)
Genetic Technologies Announces Closing of $1.44 Million Registered Direct Offering

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the "Company"), a leader in the development of genetic risk assessment tests, today announced the closing of its previously announced registered direct...

GENE : 2.32 (+1.75%)
Genetic Technologies Announces $1.44 Million Registered Direct Offering

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the "Company"), a leader in the development of genetic risk assessment tests, today announced that it has entered into definitive agreements with...

GENE : 2.32 (+1.75%)
COVID-19 Testing Capacity at Genetic Technologies Accredited Laboratory

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the "Company") has developed a detailed implementation plan to enable a temporary transition of our genetic testing laboratory to a high-throughput...

GENE : 2.32 (+1.75%)
Genetic Technologies Announces Closing of $1.8 Million Registered Direct Offering

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the "Company"), a leader in the development of genetic risk assessment tests, today announced the closing of the previously announced registered direct...

GENE : 2.32 (+1.75%)
Genetic Technologies Announces $1.8 Million Registered Direct Offering

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the "Company"), a leader in the development of genetic risk assessment tests, today announced that it has entered into definitive agreements with...

GENE : 2.32 (+1.75%)
Genetic Technologies Limited Announces Market Update on Sales, Early Test Results and Launch of Consumer Initiated Testing

Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, "Company"), provides the following update to the market.

GENE : 2.32 (+1.75%)
Genetic Technologies Limited Announces Receipt of Delisting Notification Letter from Nasdaq

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the "Company"), a leader in the development of genetic risk assessment tests, today announced that after the close of the ASX market on March 13,...

GENE : 2.32 (+1.75%)
Genetic Technologies to provide Corporate & Strategic Update at 2020 Biotech Showcase

Genetic Technologies (ASX: GTG; NASDAQ: GENE), a leader in the development of genetic risk assessment tests, recently announced the commercial availability and US launch of the company's GeneType for Breast...

GENE : 2.32 (+1.75%)
20 Medical centers across 8 US states set to offer Breast Cancer Test

Molecular diagnostics company Genetic Technologies Limited (ASX: GTG, NASDAQ: GENE) is pleased to advise that its third-generation breast cancer test (GeneType for Breast Cancer) is on track for commercial...

GENE : 2.32 (+1.75%)
Genetic Technologies to Hold Investor Webinar and Q&A Session on December 18

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, "Company") is pleased to announce its interim-CEO, Dr. Jerzy Muchnicki, will share insight into the company's recent developments during an investor...

GENE : 2.32 (+1.75%)
Genetype for Breast Cancer commissioned with sales to commence First Quarter 2020

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, "Company") is pleased to announce the full commissioning of its Australian Laboratory for the provisioning of its generation 3 breast cancer test with...

GENE : 2.32 (+1.75%)
Genetic Technologies Interview to Air on Bloomberg International on the RedChip Money Report

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, "Company"), a diversified molecular diagnostics company, announced today an interview with interim-CEO Dr. Jerzy Muchnicki will air on The RedChip...

GENE : 2.32 (+1.75%)
Genetic Technologies Provides Shareholder Update on Recent Achievements and Upcoming Milestones

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, "Company"), a diversified molecular diagnostics company, announced today an update to shareholders on recent achievements and upcoming milestones.

GENE : 2.32 (+1.75%)
Genetic Technologies Limited (ASX Code: GTG; NASDAQ Ticker: GENE) announces successful completion of two new ground-breaking Genetic Risk Tests - for Colorectal Cancer and for Breast Cancer

Genetic Technologies Limited (ASX: GTG; NASDAQ Ticker: GENE) is delighted to announce that following substantial scientific research and genetic product development, two new ground-breaking cancer risk...

GENE : 2.32 (+1.75%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS -1.57 , SEDG +2.61 , THC +0.36 , TER -1.60 , LITE -1.25
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar